Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2021

Open Access 01-12-2021 | Anticoagulant | Research

Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis

Authors: Sirui Zhang, Yupei Li, Guina Liu, Baihai Su

Published in: Thrombosis Journal | Issue 1/2021

Login to get access

Abstract

Background

Anticoagulation in hospitalized COVID-19 patients has been associated with survival benefit; however, the optimal anticoagulant strategy has not yet been defined. The objective of this meta-analysis was to investigate the effect of intermediate-to-therapeutic versus prophylactic anticoagulation for thromboprophylaxis on the primary outcome of in-hospital mortality and other patient-centered secondary outcomes in COVID-19 patients.

Methods

MEDLINE, EMBASE, and Cochrane databases were searched from inception to August 10th 2021. Cohort studies and randomized clinical trials that assessed the efficacy and safety of intermediate-to-therapeutic versus prophylactic anticoagulation in hospitalized COVID-19 patients were included. Baseline characteristics and relevant data of each study were extracted in a pre-designed standardized data-collection form. The primary outcome was all-cause in-hospital mortality and the secondary outcomes were incidence of thrombotic events and incidence of any bleeding and major bleeding. Pooled analysis with random effects models yielded relative risk with 95 % CIs.

Results

This meta-analysis included 42 studies with 28,055 in-hospital COVID-19 patients totally. Our pooled analysis demonstrated that intermediate-to-therapeutic anticoagulation was not associated with lower in-hospital mortality (RR=1.12, 95 %CI 0.99-1.25, p=0.06, I2=77 %) and lower incidence of thrombotic events (RR=1.30, 95 %CI 0.79-2.15, p=0.30, I2=88 %), but increased the risk of any bleeding events (RR=2.16, 95 %CI 1.79-2.60, p<0.01, I2=31 %) and major bleeding events significantly (RR=2.10, 95 %CI 1.77-2.51, p<0.01, I2=11 %) versus prophylactic anticoagulation. Moreover, intermediate-to-therapeutic anticoagulation decreased the incidence of thrombotic events (RR=0.71, 95 %CI 0.56-0.89, p=0.003, I2=0 %) among critically ill COVID-19 patients admitted to intensive care units (ICU), with increased bleeding risk (RR=1.66, 95 %CI 1.37-2.00, p<0.01, I2=0 %) and unchanged in-hospital mortality (RR=0.94, 95 %CI 0.79-1.10, p=0.42, I2=30 %) in such patients. The Grading of Recommendation, Assessment, Development, and Evaluation certainty of evidence ranged from very low to moderate.

Conclusions

We recommend the use of prophylactic anticoagulation against intermediate-to-therapeutic anticoagulation among unselected hospitalized COVID-19 patients considering insignificant survival benefits but higher risk of bleeding in the escalated thromboprophylaxis strategy. For critically ill COVID-19 patients, the benefits of intermediate-to-therapeutic anticoagulation in reducing thrombotic events should be weighed cautiously because of its association with higher risk of bleeding.

Trial registration

The protocol was registered at PROSPERO on August 17th 2021 (CRD42021273780).

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.PubMedPubMedCentralCrossRef
2.
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002.PubMedPubMedCentralCrossRef
3.
Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, Zhang C, Li H, Xia X, Kong S, et al. Deep Vein Thrombosis in Hospitalized Patients With COVID-19 in Wuhan, China: Prevalence, Risk Factors, and Outcome. Circulation. 2020;142(2):114–28.PubMedCrossRef
4.
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148–50.PubMedPubMedCentralCrossRef
5.
Mirsadraee S, Gorog DA, Mahon CF, Rawal B, Semple TR, Nicol ED, Arachchillage DRJ, Devaraj A, Price S, Desai SR, et al. Prevalence of Thrombotic Complications in ICU-Treated Patients With Coronavirus Disease 2019 Detected With Systematic CT Scanning. Crit Care Med. 2021;49(5):804–15.PubMedCrossRef
6.
Xiong X, Chi J, Gao Q: Prevalence and risk factors of thrombotic events on patients with COVID-19: a systematic review and meta-analysis. Thromb J. 2021, 19(1):32.PubMedPubMedCentralCrossRef
7.
8.
Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, Le Mao R, Rodríguez C, Hunt BJ, Monreal M: Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Chest 2021, 159(3):1182–1196.PubMedCrossRef
9.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H: Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020, 395(10234):1417–1418.
10.
Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, Muenchhoff M, Hellmuth JC, Ledderose S, Schulz H et al: Immunothrombotic Dysregulation in COVID-19 Pneumonia Is Associated With Respiratory Failure and Coagulopathy. Circulation 2020, 142(12):1176–1189.PubMedPubMedCentralCrossRef
11.
Iba T, Levy JH, Levi M, Thachil J: Coagulopathy in COVID-19. J Thromb Haemost 2020, 18(9):2103–2109.PubMedCrossRef
12.
Rochwerg B, Agarwal A, Siemieniuk RA, Agoritsas T, Lamontagne F, Askie L, Lytvyn L, Leo YS, Macdonald H, Zeng L et al: A living WHO guideline on drugs for covid-19. BMJ (Clinical research ed) 2020,370:m3379.
13.
Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid D, Griffin DO et al: American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood adv 2021, 5(3):872–888.PubMedPubMedCentralCrossRef
14.
Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A et al: Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020, 120(12):1597–1628.PubMedPubMedCentralCrossRef
15.
Kyriakoulis KG, Kollias A, Kyriakoulis IG, Kyprianou IA, Papachrysostomou C, Makaronis P, Kotronias RA, Terentes-Printzios D, Toskas I, Mikhailidis DP: Thromboprophylaxis in Patients with COVID-19: Systematic Review of National and International Clinical Guidance Reports. Curr Vasc Pharmacol 2021.
16.
Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV et al: Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020, 191:145–147.PubMedPubMedCentralCrossRef
17.
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, Merdji H, Clere-Jehl R, Schenck M, Fagot Gandet F et al: High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020, 46(6):1089–1098.CrossRefPubMedPubMedCentral
18.
Santoro F, Núñez-Gil IJ, Viana-Llamas MC, Maroun Eid C, Romero R, Fernández Rozas I, Aparisi A, Becerra-Muñoz VM, García Aguado M, Huang J et al: Anticoagulation Therapy in Patients With Coronavirus Disease 2019: Results From a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19]). Crit Care Med 2021, 49(6):e624-e633.PubMedCrossRef
19.
Rosovsky RP, Sanfilippo KM, Wang TF, Rajan SK, Shah S, Martin KA, F NÁ, Huisman M, Hunt BJ, Kahn SR et al: Anticoagulation Practice Patterns in COVID-19: A Global Survey. Res Pract Thromb Haemost 2020, 4(6):969–983.PubMedCentralCrossRef
20.
Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, Godier A, Testa S, Levy JH, Albaladejo P et al: Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit care (Lond, Engl) 2020, 24(1):364.CrossRef
21.
Lavinio A, Ercole A, Battaglini D, Magnoni S, Badenes R, Taccone FS, Helbok R, Thomas W, Pelosi P, Robba C: Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. Crit care (Lond, Engl) 2021, 25(1):155.CrossRef
22.
Flaczyk A, Rosovsky RP, Reed CT, Bankhead-Kendall BK, Bittner EA, Chang MG: Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: implications for clinical practice and future investigations. Crit care (Lond, Engl) 2020, 24(1):559.CrossRef
23.
Patell R, Chiasakul T, Bauer E, Zwicker JI: Pharmacologic Thromboprophylaxis and Thrombosis in Hospitalized Patients with COVID-19: A Pooled Analysis. Thromb Haemost 2021, 121(1):76–85.PubMedCrossRef
24.
Abdel-Maboud M, Menshawy A, Elgebaly A, Bahbah EI, El Ashal G, Negida A: Should we consider heparin prophylaxis in COVID-19 patients? a systematic review and meta-analysis. J Thromb Thrombolysis 2020.
25.
Wijaya I, Andhika R, Huang I: The Use of Therapeutic-Dose Anticoagulation and Its Effect on Mortality in Patients With COVID-19: A Systematic Review. Clin Appl Thromb Hemost 2020, 26.
26.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical research ed) 2009, 339:b2700.CrossRef
27.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA: The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 2011, 343:d5928.CrossRef
28.
Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010, 25(9):603–605.PubMedCrossRef
29.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed) 2008, 336(7650):924–926.CrossRef
30.
Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E et al: Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011, 123(23):2736–2747.PubMedCrossRef
31.
Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM: Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin 2012, 28(1):79–87.PubMedCrossRef
32.
Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, Gernsheimer TB, Ness PM, Brecher ME, Josephson CD et al: Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010, 362(7):600–613.PubMedPubMedCentralCrossRef
33.
Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010, 8(1):202–204.PubMedCrossRef
34.
Perepu US, Chambers I, Wahab A, Ten Eyck P, Wu C, Dayal S, Sutamtewagul G, Bailey SR, Rosenstein LJ, Lentz SR: Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. J Thromb Haemost 2021.
35.
Lopes RD, de Barros ESPGM, Furtado RHM, Macedo AVS, Bronhara B, Damiani LP, Barbosa LM, de Aveiro Morata J, Ramacciotti E, de Aquino Martins P et al: Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021, 397(10291):2253–2263.PubMedPubMedCentralCrossRef
36.
Lemos ACB, do Espírito Santo DA, Salvetti MC, Gilio RN, Agra LB, Pazin-Filho A, Miranda CH: Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID). Thromb Res 2020, 196:359–366.PubMedPubMedCentralCrossRef
37.
Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR et al: Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. N Engl J Med 2021.
38.
Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF et al: Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med 2021.
39.
Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O et al: Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thromb Haemost 2021.
40.
Yu B, Gutierrez VP, Carlos A, Hoge G, Pillai A, Kelly JD, Menon V: Empiric use of anticoagulation in hospitalized patients with COVID-19: a propensity score-matched study of risks and benefits. Biomark Res 2021, 9(1):29.PubMedPubMedCentralCrossRef
41.
Voicu S, Chousterman BG, Bonnin P, Deye N, Malissin I, Gall AL, Barthélémy R, Sutterlin L, Naim G, Mrad A et al: Increased anticoagulation reduces proximal deep vein thrombosis in mechanically ventilated COVID-19 patients: Venous thrombosis prevention & COVID-19. J Infect 2021, 82(5):186–230.PubMedCrossRef
42.
Vaughn VM, Yost M, Abshire C, Flanders SA, Paje D, Grant P, Kaatz S, Kim T, Barnes GD: Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19. JAMA netw open 2021, 4(6):e2111788.PubMedPubMedCentralCrossRef
43.
Takayama W, Endo A, Otomo Y: Anticoagulation therapy using unfractionated heparin at a therapeutic dose for coronavirus disease 2019 patients with severe pneumonia: a retrospective historical control study. Acute Med Surg 2021, 8(1):e679.PubMedPubMedCentralCrossRef
44.
Rodolfo., Aguilar-Soto M, Rodríguez-Toledo CA, Camiro-Zúñiga A, Demichelis R: The impact of different prophylactic anticoagulation doses on the outcomes of patients with COVID-19. Thromb Res 2021, 202:14–16.CrossRef
45.
Qin W, Dong F, Zhang Z, Hu B, Chen S, Zhu Z, Li F, Wang X, Zhang Y, Wang Y et al: Low molecular weight heparin and 28-day mortality among patients with coronavirus disease 2019: A cohort study in the early epidemic era. Thromb Res 2021, 198:19–22.PubMedCrossRef
46.
Poulakou G, Dimakakos E, Kollias A, Kyriakoulis KG, Rapti V, Trontzas I, Thanos C, Abdelrasoul M, Vantana T, Leontis K et al: Beneficial Effects of Intermediate Dosage of Anticoagulation Treatment on the Prognosis of Hospitalized COVID-19 Patients: The ETHRA Study. In vivo (Athens, Greece) 2021, 35(1):653–661.
47.
Pesavento R, Ceccato D, Pasquetto G, Monticelli J, Leone L, Frigo A, Gorgi D, Postal A, Marchese GM, Cipriani A et al: The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. J Thromb Haemost 2020, 18(10):2629–2635.PubMedCrossRef
48.
Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E et al: Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol 2020, 76(1):122–124.PubMedPubMedCentralCrossRef
49.
Paolisso P, Bergamaschi L, D’Angelo EC, Donati F, Giannella M, Tedeschi S, Pascale R, Bartoletti M, Tesini G, Biffi M et al: Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients. Front Pharmacol 2020, 11:1124.PubMedPubMedCentralCrossRef
50.
Pablo P, Farfán-Sedano AI, Pedrajas JM, Llamas P, Sigüenza P, Jaras MJ, Quintana-Diaz M, Fernández-Capitán C, Bikdeli B, Jiménez D et al: Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis. J Thromb Haemost 2021.
51.
Nadkarni GN, Lala A, Bagiella E, Chang HL, Moreno PR, Pujadas E, Arvind V, Bose S, Charney AW, Chen MD et al: Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19. J Am Coll Cardiol 2020, 76(16):1815–1826.PubMedPubMedCentralCrossRef
52.
Nadeem R, Thomas SJ, Fathima Z, Palathinkal AS, Alkilani YE, Dejan EA, Darwish IMI, Alsubousi AA, Backour AM, Kandeel H et al: Pattern of anticoagulation prescription for patients with Covid-19 acute respiratory distress syndrome admitted to ICU. Does it impact outcome? Heart Lung 2021, 50(1):1–5.PubMedCrossRef
53.
Musoke N, Lo KB, Albano J, Peterson E, Bhargav R, Gul F, DeJoy R, 3rd, Salacup G, Pelayo J, Tipparaju P et al: Anticoagulation and bleeding risk in patients with COVID-19. Thromb Res 2020, 196:227–230.
54.
Motta JK, Ogunnaike RO, Shah R, Stroever S, Cedeño HV, Thapa SK, Chronakos JJ, Jimenez EJ, Petrini J, Hegde A: Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in Coronavirus Disease 2019. Crit Care Explor 2020, 2(12):e0309.PubMedPubMedCentralCrossRef
55.
Moll M, Zon RL, Sylvester KW, Rimsans J, Chen EC, Ghosh AJ, Abston E, Kim A, Rutherford H, Mitre X et al: Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. Thromb Res 2021, 203:57–60.PubMedPubMedCentralCrossRef
56.
Mennuni MG, Renda G, Grisafi L, Rognoni A, Colombo C, Lio V, Foglietta M, Petrilli I, Pirisi M, Spinoni E et al: Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19. J Thromb Thrombolysis 2021:1–9.
57.
Meizlish ML, Goshua G, Liu Y, Fine R, Amin K, Chang E, DeFilippo N, Keating C, Liu Y, Mankbadi M et al: Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol 2021, 96(4):471–479.PubMedPubMedCentralCrossRef
58.
Martinelli I, Ciavarella A, Abbattista M, Aliberti S, De Zan V, Folli C, Panigada M, Gori A, Artoni A, Ierardi AM et al: Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19. Intern Emerg Med 2021, 16(5):1223–1229.PubMedCrossRefPubMedCentral
59.
Lynn L, Reyes JA, Hawkins K, Panda A, Linville L, Aldhahri W, Kango G, Shah S, Ayanian S, Teufel K: The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort. Thromb Res 2021, 197:65–68.PubMedCrossRef
60.
Longhitano Y, Racca F, Zanza C, Muncinelli M, Guagliano A, Peretti E, Minerba AC, Mari M, Boverio R, Salio M et al: Venous Thrombo-Embolism in Hospitalized SARS-CoV-2 Patients Treated with Three Different Anticoagulation Protocols: Prospective Observational Study. Biology 2020, 9(10).
61.
Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K: High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost 2020, 18(7):1743–1746.PubMedCrossRef
62.
Kodama R, Kalsi A, Singh A, Vishnuvardhan N, Nimkar N, Paul S, Usta S, Ashraf F, Mazloom A, Ashfaq A et al: Outcomes in COVID-19 patients on treatment dose anti- coagulation compared to prophylactic dose anti-coagulation. Blood 2020, 136(SUPPL 1):40–41.CrossRef
63.
Kaur J, Sule AA, Koehler T, Krishnamoorthy G, DeLongpre J: Anticoagulation management and outcomes in COVID-19 patients: A multi-center retrospective cohort study. Blood 2020, 136(SUPPL 1):34.
64.
Jonmarker S, Hollenberg J, Dahlberg M, Stackelberg O, Litorell J, Everhov Å H, Järnbert-Pettersson H, Söderberg M, Grip J, Schandl A et al: Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients. Crit care (Lond, Engl) 2020, 24(1):653.CrossRef
65.
Ionescu F, Jaiyesimi I, Petrescu I, Lawler PR, Castillo E, Munoz-Maldonado Y, Imam Z, Narasimhan M, Abbas AE, Konde A et al: Association of anticoagulation dose and survival in hospitalized COVID-19 patients: A retrospective propensity score-weighted analysis. Eur J Haematol 2021, 106(2):165–174.PubMedCrossRef
66.
Hsu A, Liu Y, Zayac AS, Olszewski AJ, Reagan JL: Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia. Thromb Res 2020, 196:375–378.PubMedPubMedCentralCrossRef
67.
Helms J, Severac F, Merdji H, Schenck M, Clere-Jehl R, Baldacini M, Ohana M, Grunebaum L, Castelain V, Anglés-Cano E et al: Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care 2021, 11(1):14.PubMedPubMedCentralCrossRef
68.
Hanif A, Khan S, Mantri N, Hanif S, Saleh M, Alla Y, Chinta S, Shrestha N, Ji W, Attwood K et al: Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. Ann Hematol 2020, 99(10):2323–2328.PubMedCrossRef
69.
Halaby R, Cuker A, Yui J, Matthews A, Ishaaya E, Traxler E, Domenico C, Cooper T, Tierney A, Niami P et al: Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study. J Thromb Haemost 2021, 19(6):1533–1545.PubMedPubMedCentralCrossRef
70.
Ferguson J, Volk S, Vondracek T, Flanigan J, Chernaik A: Empiric Therapeutic Anticoagulation and Mortality in Critically Ill Patients With Respiratory Failure From SARS-CoV-2: A Retrospective Cohort Study. J Clin Pharmacol 2020, 60(11):1411–1415.PubMedCrossRef
71.
Elmelhat A, Elbourai E, Dewedar H, Elgergawi T, Alkhanbouli M, Ahmed S, Malik Z, Nugud A, Mohammed S, Mohammad H et al: Comparison between Prophylactic versus Therapeutic Doses of Low-Molecular-Weight Heparin in Severely Ill Coronavirus Disease 2019 Patients in Relation to Disease Progression and Outcome. Dubai Med J 2020, 3(4):162–169.CrossRef
72.
Di Castelnuovo A, Costanzo S, Antinori A, Berselli N, Blandi L, Bonaccio M, Cauda R, Guaraldi G, Menicanti L, Mennuni M et al: Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: the Multicenter Italian CORIST Study. Thromb Haemost 2021.
73.
Daughety MM, Morgan A, Frost E, Kao C, Hwang J, Tobin R, Patel B, Fuller M, Welsby I, Ortel TL: COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy. Thromb Res 2020, 196:483–485.PubMedPubMedCentralCrossRef
74.
Canoglu K, Saylan B: Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. Ann Saudi Med 2020, 40(6):462–468.PubMedPubMedCentralCrossRef
75.
Bolzetta F, Maselli M, Formilan M, Busonera F, Albanese P, Chiaromanni F, Romano A, Veronese N: Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study. Aging Clin Exp Res 2021, 33(1):213–217.PubMedCrossRef
76.
Tacquard C, Mansour A, Godon A, Gruel Y, Susen S, Godier A, Albaladejo P: Anticoagulation in COVID-19: not strong for too long? Anaest Crit Care Pain Med 2021, 40(2):100857.CrossRef
77.
Cuker A, Tseng EK, Nieuwlaat R, Angchaisuksiri P, Blair C, Dane K, Davila J, DeSancho MT, Diuguid DL, Griffin DO et al: American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate intensity anticoagulation in critically ill patients. Blood adv 2021, 5 (20): 3951–3959.PubMedPubMedCentralCrossRef
78.
79.
Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG et al: Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021, 325(16):1620–1630.PubMedCrossRef
80.
Hardy M, Michaux I, Lessire S, Douxfils J, Dogné JM, Bareille M, Horlait G, Bulpa P, Chapelle C, Laporte S et al: Prothrombotic disturbances of hemostasis of patients with severe COVID-19: A prospective longitudinal observational study. Thromb Res 2021, 197:20–23.PubMedCrossRef
81.
Liao DY, Zhou F, Luo LL, Xu M, Wang HB, Xia JH, Gao Y, Cai LQ, Wang ZH, Yin P et al: Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020, 7(9):E671-E678.PubMedPubMedCentralCrossRef
82.
Godon A, Durand Z, Agier L, Lecompte T, Mullier F, Marlu R, de Maistre E, Tacquard C, Levy JH, Godier A et al: Comparison of Fibrin Monomers and D-dimers to predict thrombotic events in critically ill patients with COVID-19 pneumonia: A retrospective study. Thromb Res 2021, 205:8–10.PubMedPubMedCentralCrossRef
83.
Moosavi M, Wooten M, Goodman A, Nahab FB, Duncan A, Maier C, Guarner J: Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19. Am J Clin Pathol 2021, 155(4):498–505.PubMedCrossRef
84.
Tassiopoulos AK, Mofakham S, Rubano JA, Labropoulos N, Bannazadeh M, Drakos P, Volteas P, Cleri NA, Alkadaa LN, Asencio AA et al: D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis. Front Med 2021, 8:10.CrossRef
85.
Farrar JE, Trujillo TC, Mueller SW, Beltran L, Nguyen C, Hassell K, Kiser TH: Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19. J Thromb Thrombolysis 2021.
86.
87.
Novelli C, Borotto E, Beverina I, Punzi V, Radrizzani D, Brando B: Heparin dosage, level, and resistance in SARS-CoV2 infected patients in intensive care unit. Int J Lab Hematol 2021.
88.
White D, MacDonald S, Bull T, Hayman M, de Monteverde-Robb R, Sapsford D, Lavinio A, Varley J, Johnston A, Besser M et al: Heparin resistance in COVID-19 patients in the intensive care unit. J Thromb Thrombolysis 2020, 50(2):287–291.PubMedCrossRef
89.
Beun R, Kusadasi N, Sikma M, Westerink J, Huisman A: Thromboembolic events and apparent heparin resistance in patients infected with SARS-CoV-2. Int J Lab Hematol 2020, 42:19–20.PubMedPubMedCentralCrossRef
Metadata
Title
Intermediate-to-therapeutic versus prophylactic anticoagulation for coagulopathy in hospitalized COVID-19 patients: a systemic review and meta-analysis
Authors
Sirui Zhang
Yupei Li
Guina Liu
Baihai Su
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2021
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/s12959-021-00343-1

Other articles of this Issue 1/2021

Thrombosis Journal 1/2021 Go to the issue

Research

Evaluation of the analytical performance of the PC100 platelet counter

Research

Frequency of deep vein thrombosis at admission for acute stroke and associated factors: a cross-sectional study

Case report

Anticoagulation may contribute to antimicrobial treatment of Lemierre syndrome: a case report

Case report

Thrombotic antiphospholipid syndrome in a child with human immunodeficiency virus: a rare case report

Research

A case-control study on factor V Leiden: an independent, gender-dependent risk factor for venous thromboembolism

Research

Prognostic Value of D-dimer in patients with acute coronary syndrome treated by percutaneous coronary intervention: a retrospective cohort study
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits